Inhaled nitric oxide and heparin for infantile primary pulmonary hypertension

Lancet

Volumn 351, Issue 9117, 1998, Pages 1701-

  Atz, Andrew M ^b   Wessel, David L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; NIFEDIPINE; NITRIC OXIDE; OXYGEN; THROMBOPLASTIN;

ANGIOGENESIS; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; HUMAN; INFANT; INHALATIONAL DRUG ADMINISTRATION; LUNG VASCULAR RESISTANCE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 17644437382     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)24023-2     Document Type: Article

References (5)

1. 1 Cardelon CJ, Rylaarsdam M, Camacho L, Attie F, Zabal C, Buenida A. Primary pulmonary arterial hypertension in children under 2 years of age. Arch Inst Cardiol Mex 1991; 61: 533-37.
2. 2 Haworth SG. Pulmonary hypertension in childhood. Eur Respir J 1993; 6: 1037-43.
3. 3 Roberts JD, Roberts CT, Jones RC, Zapol WM, Bloch KD. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat. Circ Res 1995; 76: 215-22.
4. 4 Kolpakov V, Gordon D, Kulik T. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995; 76: 305-09.
5. 5 Rabinovitch M. Developmental biology of the pulmonary vasculature. In: Polin RA, Fox WW, eds. Fetal and neonatal physiology, 2nd edn. Philadelphia: WB Saunders, 1998: 913-23.